FDA grants South Texas Blood & Tissue Center first license for new process that triples shelf life of critically needed platelets
Breakthrough expected to increase availability of platelets for treating cancer patients and active bleeding cases
FDA grants South Texas Blood & Tissue Center first license for new process that triples shelf life of critically needed platelets
Breakthrough expected to increase availability of platelets for treating cancer patients and active bleeding cases